Investor Presentaiton

40 Sinopharm Performance Revenue (RMB million) 4.96% YoY 249,120 261,471 1H21 1H22 Profit Attributable Profit Attributable to Fosun Pharma (RMB million) (RMB million) 3.10% YoY 3,583 3,694 2.80% YoY 890 910 1H21 1H22 1H21 1H22 . Vigorously promoted the operational innovation and technology upgrading of pharmaceutical distribution services, enhance the scalable, professional and tailoring services advantages of pharmaceutical distribution. 1H22 revenue from pharmaceutical distribution was RMB196,523.94 million (+3.19% YoY), successfully resisted the pandemic challenge and maintained a relatively stable development trend. Utilized national leading network service capability and resource allocation advantages of medical device industry to provide all-round distribution services for various governments authorities and corporate customers. 1H22 revenue from device distribution was RMB53,684.24 million (+12.36% YoY), and the growth rate continuously surpassed the growth of the pharmaceutical distribution Made efforts to speed up the acquisition of qualifications and the introduction of varieties, continuously improved the operation efficiency and strengthened the comprehensive service capability for C-end patients and consumers. 1H22 revenue from the retail pharmacy business was RMB15,274.10 million, (+11.31% YoY), and the operating profit margin of retail business (+0.05 percentage point YoY)

View entire presentation